Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection

解读抗生素诱导的艰难梭菌感染易感性

• 批准号: 9333177
• 负责人: ROBERT A BRITTON
• 金额: $ 149.47万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-20 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9333177
• 关键词: Address; Adopted; Adult; Affect; Algorithms; Antibiotic Resistance; Antibiotic Therapy; Antibiotics; Antibodies; Antibody Response; Antitoxins; Appearance; Autistic Disorder; Bacterial Drug Resistance; Bile Acids; Biochemical Pathway; Bioinformatics; Bioreactors; Butyric Acids; Child; Childhood; Clinical; Clostridium difficile; Communities; Community Networks; Consumption; Control Groups; Coupled; Coupling; DNA; Data; Data Set; Dependency; Development; Diarrhea; Diet; Digestive System Disorders; Disaccharides; Disease; Disease Progression; Drug resistance; Ecosystem; Epidemic; Epidemiology; Etiology; Evaluation; Feces; GABA Agonists; Geography; Germination; Goals; Health Services; Heme; Hospitals; Human; Human Microbiome; Immunity; Infection; Inflammatory disease of the intestine; Intestinal Diseases; Intestines; Life; Link; Logistic Regressions; Mass Spectrum Analysis; Measures; Metabolic; Metabolic Pathway; Metadata; Metagenomics; Metronidazole; Metronidazole resistance; MicroRNAs; Microbe; Modeling; Molecular; Nosocomial Infections; Outcome; Outcome Measure; Pathogenesis; Patient risk; Patients; Population; Predisposition; Prospective Studies; Publishing; Recurrence; Refractory; Relapse; Reproduction spores; Research; Research Personnel; Resistance; Resolution; Resources; Ribotypes; Risk; Risk Factors; Role; Shotguns; Signal Transduction; Structure; Systems Biology; Technology; Testing; Texas; Treatment Failure; Treatment outcome; Trehalose; Virulence; Work; antimicrobial; base; clinical phenotype; clinical risk; cohort; enteric pathogen; experience; gamma-Aminobutyric Acid; gulf coast; gut microbiome; gut microbiota; high risk; host-microbe interactions; in vivo; innovation; insight; metabolomics; methicillin resistant Staphylococcus aureus; microbial; microbial community; microbiome; microbiota; novel diagnostics; novel therapeutics; outcome forecast; pathogen; patient registry; primary outcome; profiles in patients; public health relevance; secondary outcome; temporal measurement; trait; whole genome; zolpidem

 DESCRIPTION (provided by applicant): The Human Microbiome Project (HMP) consortium established a unique population-scale framework which characterized the relationship between the human host and its microbial communities. These data provide strong initial evidence for host influences on microbial community structure and underscores the capacity for metagenomics and metabolomics to explore host-pathogen interactions in disease states. We will adopt such a systems biology approach to extend our published and preliminary findings as they relate to Clostridium difficile infection (CDI), antibiotic resistance and treatment outcome i children and adults. By comparisons with our pediatric and adult HMP reference datasets, we provide much needed insight into how antibiotics affect intestinal ecosystems over multiple life stages. Because young children are generally asymptomatic carriers of C. difficile whereas adults often become symptomatically infected, our proposed studies provide a developmental perspective of intestinal ecosystems that modulate C. difficile virulence and drug resistance. The novelty of our work is our discovery of an intestinal ecosystem that is refractory to frontline antibiotic therapy, the result of which is treatment failure in CDI patients. Our project goal is t identify microbes that regulate host susceptibility to C. difficile through characterization of newy-identified molecular and biochemical pathways. The combination of cutting edge multi-omics, coupled with real-time measurement of antibiotic resistance and clinical phenotyping in patients is expected to generate a valuable resource that provides new discovery into host susceptibility to CDI. To achieve these objectives we will pursue two aims: Aim 1: Unbiased longitudinal multi-omic studies of host-microbe interactions in CDI development. Aim 2: Targeted mechanistic studies of host-microbe interactions that affect treatment outcome in CDI. Through these longitudinal multi-omics studies, we expect to define host-microbe interactions that are predictive of antibiotic treatment failure in CDI patients and provide a rich array of resources - supported in part by our own ongoing CDI patient registry, the Texas Department of State Health Services, Autism Speaks, the TMC Digestive Disease Center and integrated microbiome centers (Center for Metagenomics and Microbiome Research (CCMR) and Texas Children's Microbiome Center (TCMC)).

 描述（由申请人提供）：人类微生物组计划（HMP）联盟建立了一个独特的人群规模框架，该框架表征了人类宿主及其微生物群落之间的关系。这些数据为宿主对微生物群落结构的影响提供了强有力的初步证据，并强调了宏基因组学和代谢组学探索疾病状态下宿主-病原体相互作用的能力。我们将采用这种系统生物学方法来扩展我们已发表的和初步的研究结果，因为它们与艰难梭菌感染（CDI），抗生素耐药性和儿童和成人的治疗结果有关。通过与我们的儿科和成人HMP参考数据集进行比较，我们提供了抗生素如何在多个生命阶段影响肠道生态系统的迫切需要的见解。因为幼儿通常是无症状的C。艰难梭菌，而成年人往往成为肠道感染，我们提出的研究提供了肠道生态系统的发展前景，调节C。艰难梭菌的毒力和耐药性。 我们工作的新奇在于我们发现了一种肠道生态系统， 抗生素治疗，其结果是CDI患者的治疗失败。我们的项目目标是鉴定调节宿主对C.通过表征新鉴定的分子和生物化学途径来鉴定艰难梭菌。尖端的多组学结合实时测量患者的抗生素耐药性和临床表型，有望产生一种宝贵的资源，为宿主对CDI的易感性提供新的发现。为了实现这些目标，我们将追求两个目标：目标1：在CDI开发中宿主-微生物相互作用的无偏纵向多组学研究。目的2：影响CDI治疗结果的宿主-微生物相互作用的靶向机制研究。 通过这些纵向多组学研究，我们希望定义宿主-微生物相互作用，这些相互作用可以预测CDI患者的抗生素治疗失败，并提供丰富的资源-部分得到我们自己正在进行的CDI患者登记处的支持，德克萨斯州卫生服务部，Autism Speaks，TMC消化疾病中心和综合微生物组中心（宏基因组学和微生物组研究中心（CCMR）和德克萨斯州儿童微生物组中心（TCMC））。